Dahuang Qin Yu Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a brown-yellow to buff micronized multi-herb powder intended for further dosage-form processing. The botanical input consists of the dried rhizome and root of Rheum palmatum L. or Rheum tanguticum Maxim. ex Balf., the dried root of Scutellaria baicalensis Georgi, and the dried aerial parts of Houttuynia cordata Thunb.; the ratio is fixed by the controlling veterinary pharmacopoeial formula and confirmed by thin-layer chromatographic zones for emodin, chrysophanol, baicalin, and Houttuynia polyphenols. Because the API is a complex botanical matrix rather than a purified single molecule, the release specification is marker-based: baicalin and total anthraquinones calculated as emodin serve as the primary quantitative markers, while the chromatographic fingerprint serves as the identity gate. Model codes such as DQYP-80M, DQYP-10M, and DQYP-PMX represent manufacturer-specific particle-size, microbial-grade, or route-compatibility identifiers; they are not harmonized pharmacopoeial classifications, and the certificate of analysis remains the controlling document. The powder is typically controlled for loss on drying at 105 °C to constant weight, total ash, acid-insoluble ash, heavy metals by inductively coupled plasma mass spectrometry, aflatoxin B1 by LC-MS/MS, and microbial enumeration according to CVP 2020 and ISO 6579-1:2017.

Specification Logic for a Multi-Herb Veterinary API

The powder is controlled by a release specification that treats marker content, particulate size, and microbial load as interdependent variables. Marker content alone does not ensure batch-to-batch consistency, because anthraquinone glycosides in Rheum and flavonoid glycosides in Scutellaria and Houttuynia are susceptible to hydrolysis during drying and milling. Therefore, thin-layer chromatographic identity for emodin, chrysophanol, baicalin, and Houttuynia polyphenols is supplemented by quantitative HPLC-UV. A representative release profile used for oral-grade material is summarized below; injection-grade material requires additional depyrogenation and particulate controls.

The marker levels in the table are typical release limits for oral and premix grades. They are not sufficient for injection-grade use, because oral-grade milled powder can carry pyrogen and particulate burdens that pass nonsterile limits but fail USP ⟨788⟩ or CVP 2020 injection requirements. For injectable solutions, the powder must undergo extraction, cold settling, depyrogenation, and sterilizing filtration; the particle-size specification of the incoming API is then less critical than the extract’s filterability and endotoxin load.

Batch-to-batch variance in total anthraquinones is a production-scale concern: Rheum palmatum lots stored longer than 12 months may show reduced anthraquinone glycoside content, while Scutellaria baicalensis harvested before the third growth year may fall below the baicalin threshold. This shift appears as an altered HPLC area ratio of baicalin to total anthraquinones and changes the wet-mass tack in high-shear granulation because pectin and mucilage content track with the botanical source. Manufacturers should therefore link the binder addition rate to impeller power draw rather than to fixed time, because the wet granulation endpoint can drift from 4 N·m to 9 N·m within 60 seconds in 25 kg high-shear mixer campaigns. Visual adjustment of the granulating mass is not permitted; only the quantitative marker assay and the recorded power curve can justify a change in binder volume.

What Processing Limits Appear When the Powder Is Used in Injections?

Injectable use is the most restrictive conversion route. The powder cannot be directly dissolved into water for injection and filtered as a simple solution, because the Rheum fraction contains anthraquinone glycosides and tannins, while the Houttuynia fraction contributes pectin-like polysaccharides. A validated extraction procedure is required: the powder is decocted or extracted in purified water at 90–100 °C for 30–60 min, cooled to 2–8 °C for 24–48 h, and separated from the sediment by depth filtration at 10 µm. The extract is then adjusted to pH 4.5–6.5 with citrate or phosphate buffer; alkaline pH accelerates baicalin degradation and increases visible precipitate formation. The clarified liquid is membrane-filtered through 0.45 µm followed by 0.22 µm sterilizing filtration immediately before aseptic filling, or autoclaved at 121 °C for 15 min after filling. Endotoxin control must be confirmed on the extract before terminal filtration; a limit of not more than 0.5 EU/mg of dry extract or 0.5 EU/mL in the finished injection is a typical veterinary injectable requirement. Subvisible particulate matter must meet the harmonized light obscuration limits of USP ⟨788⟩ for the filled volume. Published data for this specific three-herb combination under veterinary injection GMP is limited, so process validation cannot rely on publications for single-herb Scutellaria or Rheum injectables.

Formulation incompatibilities are more severe in the injectable route than in solid oral forms. The tannin fraction forms insoluble complexes with alkaloid-containing extracts and with protein-based stabilizers; therefore, co-formulation with berberine chloride, matrine, or gelatin is contraindicated unless compatibility is proven by zeta-potential measurement and forced degradation studies. Process contact surfaces should be 316L stainless steel or glass-lined steel; unprotected copper, cast iron, and carbon steel can release metal ions that form coloured tannin complexes and reduce filter flux. In tank-holding trials, the extract should be blanketed with nitrogen if the hold time exceeds 4 h, because dissolved oxygen accelerates browning and reduces baicalin recovery due to oxidative degradation.

When Tablets and Capsules Are Manufactured from the Same API

Solid oral dosage forms use the same marker-controlled API but impose different constraints. Direct compression is possible only for low-dose formulations because the powder exhibits poor flow and high hygroscopicity. A direct-compression matrix containing microcrystalline cellulose PH102, lactose monohydrate, croscarmellose sodium 2–4%, and magnesium stearate 0.5–1.0% can be compressed on a rotary tablet press using 10–15 kN compression force for 12 mm round flat-faced tooling. Hardness is maintained at 60–100 N because lower hardness increases capping during coating and higher hardness increases disintegration beyond 30 min. Friability is controlled at not more than 1.0% after 100 revolutions. Over-lubrication with magnesium stearate above 1.0% or wet granulation with a hydrophobic binder delays baicalin release; dissolution must therefore be tested with the baicalin marker rather than a single anthraquinone marker.

For capsules, the API is blended with pregelatinized starch or lactose monohydrate to a target fill weight and filled into size 0 or size 1 hard gelatin capsules. Blend moisture above 5.0% causes auger slugging and increases capsule shell brittleness; material pre-dried to 4.0–5.0% loss on drying is required when ambient relative humidity exceeds 60%. Dissolution of the capsule product is evaluated against baicalin as the marker, with a Q value established during process validation rather than adopted from a purified single-component product. The capsule powder should not be stored in bulk for more than 72 h in an open hopper at RH 60% because moisture uptake increases the angle of repose and shifts fill-weight variation.

For oral powders, granules, premixes, and solutions, the powder is handled as an ingredient rather than a directly compressible API. Oral powder blends are prepared by geometric dilution with lactose, glucose, or soluble starch; the target coefficient of variation is not more than 5.0% at ten sampling points using the baicalin HPLC assay. Wet granulation with povidone K30 at 2–5% solids in a high-shear mixer produces 16–40 mesh granules; final loss on drying is held at 2–4% using a fluid-bed dryer with inlet air at 50–60 °C because higher temperatures with residual moisture accelerate anthraquinone glycoside hydrolysis. The premix is produced on corncob or rice hull carrier at a labelled inclusion rate, commonly 0.5–2 kg per tonne of finished feed; a horizontal ribbon mixer operating at 20 rpm for 15 min normally yields a homogeneity CV below 5.0%, but this must be confirmed by sampling. Carryover between batches is controlled by flushing with 20 kg ground corn; the flush is assayed for baicalin to verify that carryover is below the labelled limit.

In production-scale twin-shell or V-blenders, segregation of the fine API from larger carrier particles can occur after 15 min; when the blend is sampled at ten points after 10, 15, and 20 min, the optimum mixing time is selected from the time point with the lowest CV rather than from a fixed recipe. A slug addition of the API into the mixer should be avoided because it creates a local high-moisture pocket and agglomerates. The powder is layered between carrier portions, and the mixer is not filled above its rated working capacity.

Aqueous oral solutions and suspensions are prepared by wetting the API with ethanol or propylene glycol before addition to purified water; direct addition to water causes floating and clumping. The pH is adjusted to 4.5–6.5, and the suspension is screened through 74 µm before packaging. If the solution is preserved, the preservative must be selected for compatibility with the polyphenol fraction; benzalkonium chloride can form precipitates in some tannin-containing botanical solutions, but published data for this exact formulation is limited.

Material Difference from Single-Herb Rheum and Synthetic Alternatives

The principal difference between this API and a single-herb Rheum officinale API is the presence of Scutellaria baicalensis and Houttuynia cordata marker compounds. Single-herb rhubarb API is standardized on total anthraquinones—emodin, rhein, chrysophanol, aloe-emodin, and physcion—and is used primarily for its cathartic and astringent properties. Dahuang Qin Yu Powder shifts the formulation logic away from anthraquinone dose alone because baicalin from Scutellaria contributes additional polyphenol content and the Houttuynia fraction supplies volatile constituents and flavonoids. Consequently, a release specification that only measured anthraquinones would not detect batch-to-batch loss of baicalin during extraction or milling. The multi-marker approach is therefore the material difference in analytical control.

Compared with non-API ground herbal powders used in traditional veterinary practice, the veterinary-grade API is distinguishable by controlled microbial load, heavy metal limits, marker assay, and particle size. Non-API powders may meet visual identity but commonly fail Salmonella absence in 25 g by ISO 6579-1:2017 or exceed 10⁴ CFU/g total aerobic microbial count. The API is also differentiated from purified baicalin or purified rhein by the presence of the whole extract matrix; this matrix affects dissolution, hygroscopicity, and filterability. Compared with synthetic antimicrobial monotherapy, the multi-herb API is not a narrow-spectrum single entity, and its activity cannot be expressed as a single minimum inhibitory concentration against a reference strain. If a manufacturer requires a single-entity assay for regulatory submission, the baicalin or total anthraquinone marker may be selected as the analytical target, but the release of the finished product should retain the full chromatographic fingerprint to avoid unidentified component substitution.

In comparison with single-herb Scutellaria baicalensis API, this product contains Rheum-derived anthraquinones and Houttuynia-derived polyphenols; therefore, identity is not established by baicalin alone, and the dissolution plateau can differ because tannin-polysaccharide complexes in the matrix modify the release of baicalin from tablet matrices. In comparison with purified baicalin or purified rhein, the botanical matrix has a wider particle-size distribution, higher hygroscopicity, and greater sensitivity to microbial contamination; the purified compounds are assayed as single entities, whereas the API is controlled by a multivariate marker profile. The product is not a synthetic antimicrobial; if a pathogen-specific claim is required, the formulation must be supported by veterinary clinical or field efficacy data under the target regulatory framework, and a minimum inhibitory concentration for a single reference strain cannot be used as the sole release criterion.